Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

A. Ramos, Carlos; Ballard, Brandon; Zhang, Huimin; Dakhova, Olga; P. Gee, Adrian; Mei, Zhuyong; Bilgi, Mrinalini; Wu, Meng-Fen; Liu, Hao; Grilley, Bambi; M. Bollard, Catherine; H. Chang, Bill; M. Rooney, Cliona; K. Brenner, Malcolm; E. Heslop, Helen; Dotti, Gianpietro; Savoldo, Barbara

doi:10.1172/jci94306

Public

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

Published in Journal of Clinical Investigation • Aug 13, 2017

Authors:

Carlos A. Ramos

Brandon Ballard

Huimin Zhang

Abstract

BACKGROUND: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. ...

Subject

Chimeric antigen receptor

Immunology

Antigen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!